Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06635148 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

StatusRecruiting
PhasePhase 2/3
Started2024-09-19
View on ClinicalTrials.gov ↗
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

Amendment history 2 changes detected by DataLookout

2026-09-15
Phase changed: Phase 2 → Phase 2/3
2026-09-15
Primary endpoint(s) modified
WasNumber of Participants with Abnormal Findings in Clinical Laboratory Assessments, Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations, Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs)
NowChange from Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score, Number of Participants with Abnormal Findings in Clinical Laboratory Assessments, Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations, Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs)
Trial Details
NCT Number NCT06635148
Lead Sponsor Janssen Research & Development, LLC
Conditions Geographic Atrophy, Macular Degeneration
Enrollment 274 participants
Start Date 2024-09-19
Primary Completion 2029-08-24 (estimated)
Study Completion 2030-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-09-14